STEPS TAKEN AFTER THE GRANTING OF THE MARKETING 
AUTHORISATION 
For procedures finalised after 1 September 2003 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On  7  March  2002  the  European  Commission  issued  a  Decision  for  a  Type  I  variation 
(EMEA/H/C/370/I/01) for a change in the name of the Marketing Authorisation Holder (MAH) 
from Genzyme B.V. to Genzyme Europe B.V. 
On  17  September  2002  the  European  Commission  issued  a  Decision  for  a  Type  I  variation 
(EMEA/H/C/370/I/02),  for  a  change  in  test  procedure  of  active  substance  (correction  of  the 
concentration of the GZ-14 reference standard used in the IEF and peptide map assays for the 
active substance release testing). 
On  29  July  2002  the  European  Commission  issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/370/II/03) the scope of which was to change the test method and/or specifications 
for the active substance (revision of the assay method for the detection of protein impurities and 
mannose-6-phosphate in the active substance). 
On  02  December  2002  the  European  Commission  issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/370/II/04)  to  authorise  an  additional  presentation  (5  mg)  with  the  same  strength 
after reconstitution as the already authorised 35 mg presentation.  
On  24  January  2003  the  European  Commission  issued  a  Decision  on  the  1st  Annual  Re-
Assessment  (EMEA/H/C/370/S/06)  of  the  specific  obligations  and  the  benefit/risk  ratio.  No 
amendments of Annexes I and III to the Community Marketing Authorisation were necessary. 
The marketing authorisation for Fabrazyme remained under exceptional circumstances. The list 
of  Specific  obligations  set  out  in  Annex  II  was  revised  according  to  the  conclusions  of  the 
CPMP discussion. 
On  08  April  2003  the  European  Commission  issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/370/II/05)  in  order  to  add  a  new  manufacturing  site  for  the  drug  substance,  and 
scale up both the drug substance and drug product manufacturing process. 
On  19  May  2003  the  European  Commission  issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/370/II/07) relating to an update of the Summary of Product Characteristics (SPC), 
as  a  result  of  an  18-months  interim  report  of  the  ongoing  open  label  extension  phase  3  trial 
AGAL-005-99,  and  completion  of  study  01012  (evaluation  of  developmental  toxicity  in  rats) 
and  study  FB9702-01  (phase  1/2  dose  finding).  Additionally,  CPMP  recommendations 
following assessment of the 1st PSUR were implemented. 
On  22  July  2003  the  European  Commission  issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/370/II/08) relating to an update of section 4.8 of the SPC, as requested by CPMP 
following the assessment of the 2nd PSUR. 
On  05  August  2003  the  European  Commission  issued  a  Decision  on  a  Type  I  variation 
(EMEA/H/C/370/I/09) to extend the shelf life of the finished product. 
1/1 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
